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Abstract
Objective: We aimed to validate the association of genome-
wide association study (GWAS)-identified loci and polygenic 
risk score with serum thyroid-stimulating hormone (TSH) 
concentrations and the diagnosis of hypothyroidism. Then, 
the causal relationship between serum TSH and osteoporot-
ic bone fracture risk was tested. Methods: A cross-sectional 
study was done among patients of European Caucasian eth-
nicity recruited in Tayside (Scotland, UK). Electronic medical 
records (EMRs) were used to identify patients and average 
serum TSH concentration and linked to genetic biobank 
data. Genetic associations were performed by linear and lo-
gistic regression models. One-sample Mendelian random-
ization (MR) was used to test causality of serum TSH on bone 
fracture risk. Results: Replication in 9,452 euthyroid individ-
uals confirmed known loci previously reported. The 58 poly-
morphisms accounted for 11.08% of the TSH variation (p < 
1e−04). TSH-GRS was directly associated with the risk of hy-
pothyroidism with an odds ratio (OR) of 1.98 for the highest 
quartile compared to the first quartile (p = 2.2e−12). MR anal-
ysis of 5,599 individuals showed that compared with those 
in the lowest tertile of the TSH-GRS, men in the highest tertile 
had a decreased risk of osteoporotic bone fracture (OR = 
0.59, p = 2.4e−03), while no difference in a similar compari-
son was observed in women (OR = 0.93, p = 0.61). Sensitivity 
analysis yielded similar results. Conclusions: EMRs linked to 
genomic data in large populations allow replication of GWAS 
discoveries without additional genotyping costs. This study 
suggests that genetically raised serum TSH concentrations 
are causally associated with decreased bone fracture risk in 
men. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Genome-wide association studies (GWASs) have 
found association signals with serum thyroid-stimulating 
hormone (TSH) concentrations and/or hypothyroidism 
[1–4]. Replication studies in independent samples are 
scarce but desirable to help ensure that such signals are 
relevant [5].
Replication of an association requires genotyping the 
initially discovered genetic variant in a completely inde-
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
the online version of the article only. Usage and distribution for com-





pendent sample of sufficient size. Recently, electronic 
medical record (EMR)-derived phenotypes are being 
linked to genetic biobanks to allow research on the ge-
netic basis of a wide range of traits highly cost-effectively. 
Therefore, such EMR-linked biobanks might be appro-
priate to investigate the role that genetics play in thyroid-
related disorders.
A recent meta-analysis of GWAS for thyroid function 
and dysfunction, testing up to 8 million genetic variants, 
developed a TSH-based genetic risk score (GRS) and re-
ported its association with hypothyroidism, hyperthy-
roidism, and other endpoints which may be associated 
with thyroid disease [3]. Whether this TSH-GRS may be 
useful to investigate causal relationships between modifi-
able risk factors and disease outcomes also needs to be 
supported by further confirmatory studies [6].
We aimed to validate the association of GWAS-iden-
tified loci and polygenic risk score with serum TSH con-
centrations and the diagnosis of hypothyroidism in a 
Scottish population. Mendelian randomization (MR) was 
used to test the hypothesis that serum TSH concentra-
tions causally influence the risk of osteoporotic bone frac-
tures, as previous studies have shown an association [7].
Methods
A cross-sectional study was done among individuals from the 
Genetics of Diabetes and Audit Research Tayside Study (GoD-
ARTS) recruited in Tayside, Scotland (UK). All subjects in this 
population are of white ethnicity and have previously been de-
scribed [8]. EMRs (biochemistry, prescribing, hospital admissions, 
and demographics) were used to ascertain euthyroid and hypothy-
roid patients, identify those with osteoporotic bone fractures, and 
were anonymously linked to genetic biobank data by the Health 
Informatics Centre of the University of Dundee (http://www.
dundee.ac.uk/hic). Patients issued with at least 2 prescriptions for 
L-thyroxine (British National Formulary codes-BNF 6.2.1) during 
the study period (1994–2014) were defined as being hypothyroid. 
Patients with previous hyperthyroidism, identified from having 
previous thyroid surgery history by OPCS Classification of Surgi-
cal Operations and Procedures (OPCS4: B08, B09, B12), radioac-
tive iodine, and/or a prescription of anti-thyroid drug use (BNF 
6.2.2), or who had thyroid cancer from ICD codes (ICD9: 193; 
ICD10: C73, D093, D440) were excluded. The median serum TSH 
recorded throughout the study period for each patient was used. 
Euthyroid subjects had an average serum TSH concentration of 
0.4–4.0 mIU/L. The ICD codes for fractures of the vertebral col-
umn, forearm, and hip (ICD9: 733.1, 805.4, 805.5, 806.4, 806.5, 
813, 820–21; ICD10: M80, S32, S52, and S72) were considered as 
osteoporotic fractures [9].
Imputation and imputation quality of data genotyped by dif-
ferent platforms were previously described [10]. In brief, genotype 
data were available from the following platforms: the Human 
Exome-12 VI_A_chip, the Metabohip, Illumina HumanOmni Ex-
press-12 VI platform (Illumina, San Diego, CA, USA), Affymetrix 
6.0 platform (Affymetrix, Santa Clara, CA, USA), and the Illumina 
Infinium custom GWAS chip (Illumina, San Diego, CA, USA). 
Imputation was performed against 1000G Phase I V3 reference 
panel using Impute2 and using the haplotype reference consor-
tium [11]; calls made with imputation quality below 90% were dis-
carded. All single-nucleotide polymorphisms (SNPs) were in Har-
dy-Weinberg equilibrium (p < 10e−04).
Genetic tests of association were performed by linear and logis-
tic regression models. Linear regression models were used on eu-
thyroid subjects to test the association with serum TSH concentra-
tion and to estimate the variation of TSH explained by the SNPs. 
To assess the consistency of effects of this study with those previ-
ously reported, meta-analyses were performed, and heterogeneity 
was quantified using the I2 measure [12]. The combined effects of 
the genotypes were researched by GRS analyses using a weighted 
sum of TSH-increasing alleles across the 58 SNPs reported by 
Teumer et al. [3] available in our cohort and using weights from 
an external source. Participants missing >2 of these SNPs were ex-
cluded from the analyses. Association with hypothyroidism was 
performed on cases and controls by logistic regression. Odds ratios 









Missing >2 TSH-GRS SNPs




Serum TSH in the 
reference range 




No = 4,933 
Genetic data not available
(n = 5,304)  
Fig. 1. Flowchart describing the study cohort’s generation process 
and the patients included in this study. SNP, single-nucleotide 
polymorphism; TSH, thyroid-stimulating hormone; TSH-GRS, 
TSH-based genetic risk score; GoDARTS, Genetics of Diabetes 
and Audit Research Tayside Study.




To test the hypothesis that circulating TSH concentrations 
causally influence the risk of osteoporotic bone fracture, we used 
a one-sample MR design with the instrumental variable approach 
using the 2-stage method [13]. It comprised 2 regression stages: the 
first-stage linear regression of the serum TSH on the instrumental 
variable (i.e., GRS) and the second-stage regression of the osteo-
porotic bone fracture on the predicted values of the serum TSH 
from the first stage (i.e., unconfounded estimate of TSH concen-
tration attributed to these genotypes), where the second stage used 
an age-adjusted logistic regression model with robust variance to 
estimate a causal OR parameter. Sensitivity analysis was performed 
by excluding potential pleiotropic SNPs from the GRS in our MR 
analyses. The associations of the genetic variants with potential 
confounders (bone mineral density [BMD]) were annotated using 
the PhenoScanner database with the default search options [14, 
15]. All statistical analyses were conducted using STATA/SE ver-
sion 13.1 software (StataCorp, College Station, TX, USA).
Results
We identified 16,464 individuals as being eligible for 
the study after exclusion of thyroid cancer and hyperthy-
roidism cases, of which 9,452 had serum TSH within the 
reference range and had available genomic data in the 
GoDARTS biobank (see Fig. 1). Hypothyroid cases were 
more likely to be female (73 vs. 43.4%, p < 1e−03) and had 
a higher average serum TSH concentration (2.2 vs. 1.7 
mIU/L, p < 1e−03) than nonhypothyroid controls, but 
there was no difference in age (57 years).
For all participants with a serum TSH in the reference 
range (n = 9,452), we confirmed the association of serum 
TSH with known loci previously reported at CAPZB, 
NFIA, VAV3, IGFBP5, SYN2, NR3C2, PDE8B, VEGFA/
LOC100132354, PDE10A, NRG1, GLIS3, PRDM11, 
ITPK1, FAM227B/FGF7, DET1, MAF, INSR, and FOXA2 
(Table  1). Each copy of the TSH-increasing allele of 
rs2127387 at PDE8B (phosphodiesterase type 8B) was as-
sociated with an increase of 0.13 mIU/L serum TSH. This 
SNP accounted for 1.64% of serum TSH variation, fol-
lowed by signals in the phosphodiesterase type 10A 
(PDE10A-rs1079418) and the capping protein-actin fila-
ment muscle Z-line β (CAPZB-rs10917469) that contrib-
uted to 0.70% and 0.62% of variation, respectively. Fur-
ther adjustment of regression models for age and gender 
did not change the size and direction of the effect esti-
mates. We also validated novel loci at DIRC3, IGF2BP2, 
PSORS1C1, SLC25A37, SULF1, TG, C9orf92, GATA3, 
SPATA13, TSHR, MIR365A, and BCAS3. When com-
bined, the 58 SNPs accounted for 11.08% (n = 2,089, p < 
1e−04) of the variation in serum TSH concentration that 
increased to 11.65% after also including age and gender 
as predictors in the linear model, thus leaving 0.57% (i.e., 
11.65–11.08%) of the variation to age and gender. Male 
gender was associated with a lower serum TSH (β = 
−0.043, p = 1.8e−02), and each additional year of life con-
ferred an increase of 0.005 mIU/L serum TSH (p = 
3.5e−05). Although an I2 value of 0% (i.e., no observed 
heterogeneity) was obtained in the majority of the meta-
analyses, a significant heterogeneity was detected in 5 
(Table  1; SASH1-rs9497965, ABO-rs8176645, MBIP-
rs398745, SOX9-rs1042673, and HES1-rs59381142 
showed an effect about 4 times smaller in our study). Eu-
thyroid individuals carrying greater numbers of serum 





















Female (p = 3.9e-09)
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Fig. 2. Associations of TSH-based GRS 
with the probability of hypothyroidism (a) 
and osteoporotic-related bone fractures 
(b). Histogram represents the distribution 
of the polygenic risk score in the study sam-
ple. TSH, thyroid-stimulating hormone; 
GRS, genetic risk score; GoDARTS, Genet-
ics of Diabetes and Audit Research Tayside 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TSH-raising alleles had increased serum TSH concentra-
tion (β = 0.67, 95% CI 0.61–0.73, p = 2.0e−108).
The TSH-GRS was associated with the risk of hypothy-
roidism in 6,759 individuals (1,153 cases and 5,606 con-
trols) with an OR of 1.32 (95% CI 1.09–1.62, p = 5.2e−03), 
1.56 (95% CI 1.28–1.89, p = 8.8e−06), and 1.98 (95% CI 
1.63–2.40, p = 2.2e−12) for the second, third, and fourth 
quartiles, respectively, compared to the first quartile. Fig-
ure 2a shows the risk of hypothyroidism across the range 
of TSH-GRS by gender. Figure 2b shows the risk of osteo-
porotic bone fracture across the range of TSH-GRS by 
gender. Male carriers of greater numbers of TSH-raising 
alleles were at decreased risk of fractures.
The description of euthyroid patients with osteopo-
rotic bone fractures (n = 666) and their comparison co-
hort (n = 4,933) is described in Table 2. Age-sex-adjusted 
serum TSH was inversely related to bone fractures with 
an OR of 0.68 (95% CI 0.55–0.84, p = 3.8e−04) for the 
highest tertile, where average TSH concentrations per 
tertile were 1.07, 1.77, and 2.71 mIU/L, respectively. MR 
analysis showed that compared with the lowest tertile, 
those in the highest tertile had an OR of 0.77 (95% CI 
0.63–0.94, p = 1.2e−02). Men in the highest tertile had an 
OR of 0.59 (95% CI 0.42–0.83, p = 2.6e−03, n = 3,413), 
while women in a similar comparison had an OR of 0.93 
(95% CI 0.71–1.21, p = 0.61, n = 2,193). As part of the 
sensitivity analyses, we repeated this MR analysis after 
removing SNPs with potential pleiotropic effects that 
might confound the relationship between TSH and osteo-
porotic bone fracture. Four variants associated with TSH 
were also found to be significantly associated with BMD: 
SYN2-rs1663070, ABO-rs8176645, CADM1-rs4445669, 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Description of genotyped euthyroid patients with osteo-







Gender – female, n (%) 428 (64.2) 1,758 (35.6) <0.001
Diabetes mellitus, n (%) 646 (97.0) 4,796 (97.2) 0.740
Mean (SD)
Age, years 64.4 (10.6) 58.5 (12.1) <0.001
BMI, kg/m2 29.1 (5.2) 30.9 (5.6) <0.001
Serum TSH, mU/L* 1.7 (1.2–2.3) 1.8 (1.3–2.4) 0.009
BMI, body mass index; TSH, thyroid-stimulating hormone. 
* Median (interquartile range) of measurements recorded through-





TSH-GRS of 54 variants yielded a similar OR for bone 
fracture per unit increase in serum TSH (mIU/L) of 0.63 
(95% CI 0.45–0.88, p = 6.7e−03, n = 3,575) for men in the 
highest tertile compared to the lowest, while no difference 
in a similar comparison was observed in women 
(OR = 0.99, 95% CI 0.81–1.37, p = 6.8e−01, n = 2,292).
Discussion
This record linkage study used electronic databases to 
validate genetic loci discovered in GWAS with hypothy-
roidism and serum TSH concentrations in a Scottish 
Caucasian population from the GoDARTS database. Us-
ing MR, this study showed a causal (inverse) link between 
serum TSH concentrations and osteoporotic bone frac-
ture for men.
GoDARTS is a longitudinal cohort, and thus more 
than one serum TSH was available for the majority of par-
ticipants (i.e., 8 measurements on average). Although the 
number of TSH measurements would not affect our re-
sults, the use of an average TSH reflects the TSH concen-
tration better than a single measurement as in a cross-
sectional study. The consistency of SNP effects on serum 
TSH of this study with the previously reported by Teum-
er et al. [3] was demonstrated, and any discrepancies 
seem to be explained mostly by differences in the way 
TSH measurement was done or by chance. Our study ac-
counted for a larger serum TSH variation (11.6%) than 
that provided to us by Teumer et al. [3] (9.35%), but also 
than that reported by Taylor et al. [2] (7.1%) and Salem et 
al. [4] (5.8%). We acknowledge that the higher explained 
variance observed here could be because of some differ-
ences in sample size and/or allele frequency. However, 
the cohorts used for our study and those used by Teumer 
et al. [3] are of the same ethnicity-white European cohort, 
which is reflected in the similar allele frequencies ob-
served across these 2 study populations. Thus, it seems 
unlikely that as the causal variants have still not been con-
firmed through functional studies, the Scottish popula-
tion could have a different LD structure between these 
common SNPs and the causal variants. This finding in 
our cohort has been pointed out in a previous publication 
[10]. Like Teumer et al. [3], the TSH-GRS was associated 
with the risk of hypothyroidism in men and women, and 
it showed a higher risk for females.
The strength of the association between the TSH-GRS 
and serum TSH was confirmed by an F-statistic of 179, 
indicating that our instrument is strong and therefore un-
likely to be susceptible to weak instrument bias [17]. 
Thus, under the assumption that this TSH-GRS is a valid 
instrument for serum TSH concentration, we estimated 
the causal effect of serum TSH on osteoporotic-related 
bone fractures using MR analyses. In our euthyroid co-
hort, serum TSH was significantly inversely related to os-
teoporotic bone fracture, but only male carriers of greater 
numbers of TSH-raising alleles were at decreased risk. Al-
though women showed a higher risk of osteoporotic bone 
fractures, there was not a significant difference between 
carriers of greater numbers of TSH-raising alleles (high-
est tertile) and lower carriers. We observed a very small 
nonsignificant protective effect for the highest tertile in 
women (OR = 0.93, p = 0.61).
Serum TSH concentrations have been associated with 
bone fractures in published observational studies [7, 18–
20]. These studies reported that lower concentrations of 
TSH were associated with an increased risk of osteoporo-
sis and fractures [19]. Data on women from these studies 
were mostly from healthy post-menopausal females (i.e., 
group at highest risk) but also from younger women [7, 
19]. However, women in our study cohort were older than 
58 years on average (i.e., many with post-menopausal sta-
tus) and the MR analysis showed their risk of osteoporot-
ic bone fractures was independent of serum TSH within 
the normal range. Although we still do not know the un-
derlying mechanisms for sex differences in our results, we 
hypothesize that it could be related to menopausal chang-
es that happen in women but not in men. Menopausal 
changes are likely to have a greater impact on osteopo-
rotic bone fracture risk than variation in normal thyroid 
function in women. Thus, changes in estrogen status may 
be hiding the impact on fractures of differences in serum 
TSH in women that were observed in men. It is also pos-
sible that given that some TSH-increasing alleles showed 
a different impact on serum TSH variability in women 
compared to men [1, 21], unknown gender-specific effects 
of TSH could help to explain our findings as well.
In order to improve the reliability of our MR results and 
to ensure that there were no obvious pleiotropic SNPs in 
the GRS, we performed a sensitivity analyses by excluding 
potential pleiotropic variants. Thus, we repeated the MR 
analysis after removing SNPs with horizontal pleiotropic 
effects that might confound the relationship between TSH 
and osteoporotic bone fractures. The associations of the 
genetic variants used as genetic instruments with BMD 
were annotated using the PhenoScanner database. Four 
variants in chromosomes 3, 9, 11, and 16 were significant-
ly associated with BMD and thus removed from the GRS. 
This additional MR analysis yielded similar results. Other 
potential confounders that could have been considered 




(i.e., diabetes mellitus, body mass index, or smoking) 
would mostly relate to bone fracture through their effect 
on BMD as well [22, 23]. Obviously, we can never exclude 
unknown pleiotropy, but having similar results after exclu-
sion of these variants should at least address this concern.
We acknowledge that a nonlinear model does not 
guarantee that the residuals from the second-stage regres-
sion are uncorrelated with the instruments in a one-sam-
ple MR with a dichotomous outcome. However, the 
2-stage estimator with a logistic second-stage model still 
provides a valid test of the null hypothesis [13]. We also 
acknowledge that a 2-sample MR would have been better 
to deal with potential pleiotropy, but we did not have 
available an additional sample from the same population 
with individual-level data.
In conclusion, we have shown that EMR-linked genom-
ic data allowed replication of previously identified SNPs as-
sociated with several thyroid-related traits without addi-
tional genotyping costs. This study provided information 
that genetically raised serum TSH concentrations are caus-
ally associated with decreased osteoporotic bone fracture 
risk in men, but not in women. Our results also suggest 
potential benefits for monitoring TSH in euthyroid men 
who may be at particular risk of avoidable bone fractures 
and implications for fracture risk stratification.
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